An advisory panel to the US Food and Drug Administration (FDA) has voted to loosen restrictions on several peptides that have gained popularity online despite limited research into their effects on humans. The panel's narrow vote could be a significant regulatory step toward making compounds like BPC-157, TB-500, and KPV available by prescription through specialized pharmacies.
Peptides, which are small proteins naturally produced by the body, play crucial roles in various biological functions. While some peptides are approved for medical use, such as in treating diabetes, unregulated injectable peptides have seen a surge in popularity within the online wellness community, especially among young influencers. These substances are often marketed for unproven uses, including anti-aging, enhanced healing, and increased muscle mass, sometimes under terms like "biohacking" and "looksmaxxing."
Health experts have expressed caution regarding the use of these peptides due to a lack of clinical trials in humans and uncertainty about their long-term effects. BPC-157, derived from stomach protein, is marketed online for gut health, tissue repair, and inflammation reduction, with some animal studies exploring its potential for muscle healing. However, the US Anti-Doping Agency notes that its safe dosage and efficacy in humans remain unknown, and it is considered a prohibited substance in sports.
KPV is also promoted for benefits to gut health, skin repair, and immune system regulation. Both BPC-157 and KPV have existed in a regulatory gray area, being available for purchase online but not approved for human use, thus bypassing pharmaceutical quality controls.
The FDA is not obligated to follow the panel's recommendations, but it often does. Restrictions on these peptides were previously tightened during the Biden administration due to safety concerns identified by FDA officials. Health Secretary Robert F Kennedy, who has previously expressed support for easing these curbs, has described himself as a "big fan" of such drugs.
During deliberations, panel members who voted to loosen restrictions reportedly cited considerations of "the greater good" and "medical freedom." Conversely, one panel member noted voting against BPC-157 due to a perceived lack of efficacy data and safety concerns. The panel, which includes individuals affiliated with clinics and businesses selling peptides, was scheduled to continue its discussions. The substances under consideration are among seven peptides for which the panel is weighing a reduction in restrictions, allowing compounding pharmacies to produce them.